2012 was good, but not great, for biotech VC

01/31/2013 | Forbes

Upfront deal values for venture capital-backed biotech mergers and acquisitions totaled about $3.5 billion last year, which is lower than in 2011 but better than 2008 to 2010, according to data from HBM Partners. Total annual VC-backed private acquisitions have held steady since 2005. The time period from founding to trade sale appears to have risen from about five years in 2005 to nine years in 2012, notes Atlas Venture partner Bruce Booth.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA